Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
MUKnineb
MUK Nine b: OPTIMUM Treatment Protocol
- NCT03188172 ↗
- Unknown
- University of Leeds
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- MUK Nine b: OPTIMUM. A Phase II Study Evaluating Optimised Combination of Biological Therapy in Newly Diagnosed High Risk Multiple Myeloma and Plasma Cell Leukaemia.
- Phase
- Phase 2
- Status
- Unknown
- Conditions
- Multiple Myeloma
- Interventions
- Cyclophosphamide; Bortezomib; Lenalidomide; Daratumumab; Dexamethasone; Melphalan; Filgrastim
- Arms
- Trial Treatment · Experimental
- Enrollment
- 95 (estimated)
- Primary outcomes
- Progression free survival
- Sponsor
- University of Leeds with Myeloma UK, Celgene, Janssen, LP
- Start
- Sep 28, 2017
- Primary completion
- Oct 1, 2025 (estimated)
- Results posted
- No
- Registry record
- NCT03188172 · updated May 14, 2024
Publications
linked from the registry- Kaiser MF, Phillip RH, Brown SR, Holroyd A, Ferris E, de Tute RM, Roberts S, Clayton L, Bowles K, Garg M, Lokare A, Messiou C, Houlston RS, Jackson G, Cook G, Owen RG, Drayson MT, Pratt G, Hall A, Jenner MW. Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial. Lancet Oncol. 2026 Sep 7:S1470-2045(26)00286-X. doi: 10.1016/S1470-2045(26)00286-X. Online ahead of print. PubMed 42705255
- Keaveney S, Dragan A, Rata M, Blackledge M, Scurr E, Winfield JM, Shur J, Koh DM, Porta N, Candito A, King A, Rennie W, Gaba S, Suresh P, Malcolm P, Davis A, Nilak A, Shah A, Gandhi S, Albrizio M, Drury A, Pratt G, Cook G, Roberts S, Jenner M, Brown S, Kaiser M, Messiou C. Image quality in whole-body MRI using the MY-RADS protocol in a prospective multi-centre multiple myeloma study. Insights Imaging. 2023 Oct 15;14(1):170. doi: 10.1186/s13244-023-01498-3. PubMed 37840055
- Kaiser MF, Hall A, Walker K, Sherborne A, De Tute RM, Newnham N, Roberts S, Ingleson E, Bowles K, Garg M, Lokare A, Messiou C, Houlston RS, Jackson G, Cook G, Pratt G, Owen RG, Drayson MT, Brown SR, Jenner MW. Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma. J Clin Oncol. 2023 Aug 10;41(23):3945-3955. doi: 10.1200/JCO.22.02567. Epub 2023 Jun 14. PubMed 37315268
- Rata M, Blackledge M, Scurr E, Winfield J, Koh DM, Dragan A, Candito A, King A, Rennie W, Gaba S, Suresh P, Malcolm P, Davis A, Nilak A, Shah A, Gandhi S, Albrizio M, Drury A, Roberts S, Jenner M, Brown S, Kaiser M, Messiou C. Implementation of Whole-Body MRI (MY-RADS) within the OPTIMUM/MUKnine multi-centre clinical trial for patients with myeloma. Insights Imaging. 2022 Jul 28;13(1):123. doi: 10.1186/s13244-022-01253-0. PubMed 35900614
- Oliva S, Kaiser MF. Is it time to tailor treatment on the basis of minimal residual disease in multiple myeloma? Lancet Haematol. 2021 Dec;8(12):e876-e877. doi: 10.1016/S2352-3026(21)00341-0. No abstract available. PubMed 34826409
- Pawlyn C. High-risk myeloma: a challenge to define and to determine the optimal treatment. Lancet Haematol. 2021 Jan;8(1):e4-e6. doi: 10.1016/S2352-3026(20)30361-6. Epub 2020 Dec 22. No abstract available. PubMed 33357481